Actualités

Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.

Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues that Eli Lilly’s ads misrepresent clinical comparisons and risk misleading consumers and healthcare professionals. The case highlights rising tensions as both companies compete in the fast growing market for GLP-1 based obesity and diabetes treatments. Novo Nordisk is a major player in diabetes and obesity treatments,...

(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo

Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95.

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo

INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.

Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Strong demand helps the Lilly-backed biotech raise nearly $129 million

The Danish drugmaker alleges Lilly's advertising misrepresents comparisons between rival obesity treatments.

Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic

Friday’s preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.

Novo Nordisk (NYSE:NVO) has asked a U. S.

Novo Nordisk said it asked a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive advertising to mislead consumers in a lawsuit. Friday’s preliminary injunction request, filed in the District of New Jersey, escalates legal proceedings initiated earlier this week. Novo has now asked the court to stop Eli Lilly from advertising its GLP-1 drugs while the lawsuit proceeds.

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

There are plenty of reasons to love these companies.

Find insight on Roche Holding and Olympus in the latest Market Talks covering the health care sector.

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Two more Phase 3 trials showed weight loss above 20%

Retatrutide delivered substantial weight loss in two additional late-stage trials.

Drugmaker Eli Lilly said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year. Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off. Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.

Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators.

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...

If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.